Eli Casdin - 20 Jun 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director, 10%+ Owner
Signature
/s/ Eli Casdin by Tomone Tanaka, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
20 Jun 2025
Net transactions value
$0
Form type
4
Filing time
24 Jun 2025, 18:57:24 UTC
Previous filing
07 Aug 2025
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Casdin Eli Director, 10%+ Owner C/O STANDARD BIOTOOLS INC., 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO /s/ Eli Casdin by Tomone Tanaka, Attorney-in-Fact 24 Jun 2025 0001534264

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +94,592 +3.4% $0.000000 2,901,062 20 Jun 2025 Direct F1
holding LAB Common Stock 13,939,637 20 Jun 2025 Casdin Private Growth Equity Fund II, L.P. F2
holding LAB Common Stock 2,744,219 20 Jun 2025 By Casdin Private Growth Equity Fund, L.P. F3
holding LAB Common Stock 59,391,780 20 Jun 2025 Casdin Partners Master Fund, L.P F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to buy) Award $0 +125,660 $0.000000 125,660 20 Jun 2025 Common Stock 125,660 $1.05 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2 The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F3 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F4 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F5 The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.